In a cell line derived from a normal cell (no mutator phenotype) of a person considered with low cancer risk after pedigree analysis, it is possible now to introduce a heterozygous mutation in a cancer risk-associated gene (e.g., BRCA1) and to compare the mutational signatures obtained before and after in vitro mutagenesis. This evidence concerns the gene BRCA1 and cancer.